Myeloproliferative Neoplasms Clinical Trials

53 clinical trials for Myeloproliferative Neoplasms across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Exercise Training in Patients With Myeloproliferative Neoplasms — RECRUITING · NA
• A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms — RECRUITING · PHASE1
• A Phase 1 Study of PRT12396 in Participants With Select Myeloproliferative Neoplasms — RECRUITING · PHASE1
• Study of INCA036978 in Participants With Myeloproliferative Neoplasms — RECRUITING · PHASE1
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis — RECRUITING · PHASE1
• A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCA036978 IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS — RECRUITING · PHASE1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — RECRUITING · PHASE1
• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCB160058 IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS — RECRUITING · PHASE1
• Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation — RECRUITING · PHASE1
• Long-term Efficacy of Once Daily Versus Twice Daily Aspirin in High-risk MPN Patients With Aspirin Resistance — RECRUITING · PHASE3
• A PHASE 1, OPEN-LABEL, MULTICENTER STUDY OF INCA033989 ADMINISTERED AS A MONOTHERAPY OR IN COMBINATION WITH RUXOLITINIB IN PARTICIPANTS WITH MYELOPROLIFERATIVE NEOPLASMS — RECRUITING · PHASE1
• PROTOCOL 10538, VENETOCLAX IN COMBINATION WITH ASTX727, AN ALL-ORAL THERAPY FOR CHRONIC MYELOMONOCYTIC LEUKEMIA AND OTHER MDS/MPN WITH EXCESS BLASTS (VICTORY-MDS/MPN): A RANDOMIZED, PHASE 2 TRIAL — RECRUITING · PHASE2
• A PHASE II OPEN-LABEL STUDY OF COMBINED RUXOLITINIB AND ENASIDENIB IN PATIENTS WITH ACCELERATED/BLAST-PHASE MYELOPROLIFERATIVE NEOPLASM OR CHRONICPHASE MYELOFIBROSIS WITH AN IDH2 MUTATION — RECRUITING · PHASE2
• A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOMITANT JAK2 INHIBITOR THERAPY AND WHO REQUIRE RED BLOOD CELL TRANSFUSIONS — RECRUITING · PHASE3
• SL-401 IN PATIENTS WITH ADVANCED, HIGH RISK MYELOPROLIFERATIVE NEOPLASMS — RECRUITING
• A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms — NOT_YET_RECRUITING · PHASE1
• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — ACTIVE_NOT_RECRUITING · PHASE1
• A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms — ACTIVE_NOT_RECRUITING · PHASE1
• A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms — NOT_YET_RECRUITING · PHASE1
• Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations — ACTIVE_NOT_RECRUITING · PHASE1
• Interleukin-1 inhibition to improve the response of myeloproliferative neoplasms resistant to cytoreductive treatment — NOT_YET_RECRUITING · PHASE2
• A Multicenter, Open-Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Participants Enrolled in a Prior Bomedemstat Clinical Study — TERMINATED · PHASE3
• Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative Neoplasms — NOT_YET_RECRUITING · PHASE2
• A Study of TQ05105 Tablets in Subjects With Myeloproliferative Neoplasms — COMPLETED · PHASE1
• A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms. — OTHER · PHASE1
• A study to evaluate the effects and safety of INCA033989 in participants with myelofibrosis or essential thrombocythemia — TERMINATED · PHASE1
• Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood Disorders — ACTIVE_NOT_RECRUITING · PHASE2
• WELL-MPN: A Digital Lifestyle App for Patients With MPNs — NOT_YET_RECRUITING · NA
• A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT — ACTIVE_NOT_RECRUITING · PHASE1
• Hematological Disorders in EHPVO Patients — NOT_YET_RECRUITING
• A Study of VAC85135, a Neoantigen Vaccine Regimen, Concurrently Administered With Ipilimumab for the Treatment of Myeloproliferative Neoplasms — COMPLETED · PHASE1
• Registry of Patients With MPNs in Taiwan — ACTIVE_NOT_RECRUITING
• Clinical Significance of Leukocyte Cell Population Data in Patients With Myeloproliferative Neoplasms (MPNs) — NOT_YET_RECRUITING
• Physical well-being and movement behaviour of patients with myeloproliferative neoplasia (MPN) or mastocytosis — OTHER
• AN OPEN-LABEL, MULTICENTER, EXTENSION STUDY FOR PATIENTS PREVIOUSLY ENROLLED IN STUDIES WITH PELABRESIB — NOT_YET_RECRUITING
• Expression Pattern of HNRNPH1 and HNRNPK Genes in MPNs — OTHER
• Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms — COMPLETED · NA
• A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY OF PRT1419 INJECTION AS MONOTHERAPY OR IN COMBINATION WITH AZACITIDINE OR VENETOCLAX IN PATIENTS WITH RELAPSED/REFRACTORY MYELOID OR B-CELL MALIGNANCIES — COMPLETED · PHASE1
• The First-in-human Phase I Trial of PU-H71 in Patients With Advanced Malignancies — COMPLETED · PHASE1
• Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) — TERMINATED · PHASE1
• Jaktinib and Azacitidine In Treating Patients With MDS With MF or MDS/MPN With MF. — TERMINATED · PHASE1
• A Phase II Study of SGI-110 in Philadelphia-Negative Myeloproliferative Neoplasms — COMPLETED · PHASE2
• VENETOCLAX AND AZACITIDINE COMBINATION THERAPY FOR PATIENTS WITH ACCELERATED OR BLAST PHASE BCR-ABL NEGATIVE MYELOPROLIFERATIVE NEOPLASM (VAAMP) — NOT_YET_RECRUITING
• A PHASE 2 PILOT RANDOMIZED CONTROLLED TRIAL ASSESSING FEASIBILITY OF THROMBOPROPHYLAXIS WITH APIXABAN IN JAK2-POSITIVE MYELOPROLIFERATIVE NEOPLASM PATIENTS — COMPLETED · PHASE2
• Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML — COMPLETED · PHASE1
• Clinical and Therapeutic Impact of Molecular Markers in Myeloproliferative Disorders — OTHER
• Pomalidomide in Patients With Myeloproliferative Neoplasms in Fibrotic Stage — COMPLETED · PHASE2
• A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders — COMPLETED · PHASE2

Refine this search